In acute promyelocytic leukemia, FoxO3a has been shown to be a key effector in differentiation‐based therapy by all‐trans retinoic acid, whereas in mixed‐lineage AML, FoxO3a activity favors disease progression, and its high expression is associated with AML stem cell pool expansion [125, 126, 127]. The gene discussed is FOXO3; the disease is acute promyelocytic leukemia.